Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Adenoid cystic carcinoma with solid histology or high-grade transformation

3 evidence topics · 4 sources

Summary: prevalence of ACC and of the aggressive subgroup

No published source reports the prevalence of ACC with solid histology or high-grade transformation. For ACC overall, Servier reports that more than 200,000 people have ACC worldwide. For all salivary gland cancers, the estimated global 1-year prevalence is about 42,000 cases (GLOBOCAN 2022). A 2020 ASCO abstract on the epidemiology of ACC in the United States could not be retrieved for quotation. Because survival in aggressive ACC is shorter than in ACC-II (median overall survival 3.44 versus 23.2 years in a proteogenomic cohort of 54 participants), the aggressive subgroup is expected to represent a smaller share of prevalent cases than of incident cases.